-
Something wrong with this record ?
Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
AM. Rulseh, J. Keller, J. Klener, J. Sroubek, V. Dbalý, M. Syrůček, F. Tovaryš, J. Vymazal,
Language English Country England, Great Britain
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
NLK
BioMedCentral
from 2003-01-12
BioMedCentral Open Access
from 2003
Directory of Open Access Journals
from 2003
Free Medical Journals
from 2003
PubMed Central
from 2003
Europe PubMed Central
from 2003 to 2020
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2003-02-01
Open Access Digital Library
from 2003-01-01
Open Access Digital Library
from 2003-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2003
Springer Nature OA/Free Journals
from 2003-12-01
- MeSH
- Adult MeSH
- Electric Stimulation Therapy * MeSH
- Glioblastoma mortality pathology therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local mortality pathology therapy MeSH
- Magnetic Resonance Imaging MeSH
- Survival Rate MeSH
- Brain Neoplasms mortality pathology therapy MeSH
- Pilot Projects MeSH
- Prognosis MeSH
- Aged MeSH
- Neoplasm Grading MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024212
- 003
- CZ-PrNML
- 005
- 20200131104353.0
- 007
- ta
- 008
- 130703s2012 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/1477-7819-10-220 $2 doi
- 035 __
- $a (PubMed)23095807
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rulseh, Aaron Michael $7 xx0243723 $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic
- 245 10
- $a Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields / $c AM. Rulseh, J. Keller, J. Klener, J. Sroubek, V. Dbalý, M. Syrůček, F. Tovaryš, J. Vymazal,
- 520 9_
- $a Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádory mozku $x mortalita $x patologie $x terapie $7 D001932
- 650 12
- $a elektrostimulační terapie $7 D004599
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glioblastom $x mortalita $x patologie $x terapie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a lokální recidiva nádoru $x mortalita $x patologie $x terapie $7 D009364
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Keller, Jiří $u -
- 700 1_
- $a Klener, Jan $u -
- 700 1_
- $a Sroubek, Jan $u -
- 700 1_
- $a Dbalý, Vladimír $u -
- 700 1_
- $a Syrůček, Martin $u -
- 700 1_
- $a Tovaryš, František $u -
- 700 1_
- $a Vymazal, Josef $u -
- 773 0_
- $w MED00008253 $t World journal of surgical oncology $x 1477-7819 $g Roč. 10(2012), s. 220
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23095807 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20200131104736 $b ABA008
- 999 __
- $a ok $b bmc $g 987892 $s 822592
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 10 $d 220 $i 1477-7819 $m World journal of surgical oncology $n World J Surg Oncol $x MED00008253
- LZP __
- $a Pubmed-20130703
